Fibroblast growth factor 23

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 203-227

  Smith, Edward R ^a   McMahon, Lawrence P ^a   Holt, Stephen G ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

chronic kidney disease; enzyme linked immunosorbent assay; Fibroblast growth factor 23; method comparison; parathyroid hormone

Indexed keywords

CHRONIC KIDNEY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 23; METHOD COMPARISON; PARATHYROID HORMONE;

ANIMALS; CLINICAL CHEMISTRY TESTS; FIBROBLAST GROWTH FACTORS; HUMANS; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84898677307     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213510708     Document Type: Review

References (137)

1. Shimada T,Hasegawa H,Yamazaki Y, et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.J Bone Miner Res. 2004;19:429-435.
2. Kurosu H,Ogawa Y,Miyoshi M, et al.Regulation of fibroblast growth factor-23 signaling by klotho.J Biol Chem. 2006;281:6120-6123.
3. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348.
4. Shimada T,Mizutani S,Muto T, et al.Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.Proc Natl Acad Sci USA. 2001;98:6500-6505.
5. Moe SM,Drueke T,Lameire N, et al.Chronic kidney disease-mineral-bone disorder: A new paradigm.Adv Chronic Kidney Dis. 2007;14:3-12.
6. Isakova T,Wahl P,Vargas GS, et al.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int. 2011;79:1370-1378.
7. Pereira RC,Juppner H,Azucena-Serrano CE, et al.Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.Bone. 2009;45:1161-1168.
8. Pavik I,Jaeger P,Kistler AD, et al.Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.Kidney Int. 2011;79:234-240.
9. Westerberg PA,Ljunggren O,Larsson TE, et al.Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy.Nephrol Dial Transplant. 2010;25:4068-4071.
10. Isakova T,Wahl P,Vargas GS, et al.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int. 2011;79:1370-1378.
11. Hasegawa H,Nagano N,Urakawa I, et al.Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.Kidney Int. 2010;78:975-980.
12. Craver L,Marco MP,Martinez I, et al.Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges.Nephrol Dial Transplant. 2007;22:1171-1176.
13. Martinez I,Saracho R,Montenegro J, et al.A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism.Nephrol Dial Transplant. 1996;11:22-28.
14. Hill KM,Martin BR,Wastney ME, et al.Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.Kidney Int. 2013;83:959-966.
15. Gutierrez O,Isakova T,Rhee E, et al.Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.J Am Soc Nephrol. 2005;16:2205-2215.
16. Gutierrez OM,Mannstadt M,Isakova T, et al.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.N Engl J Med. 2008;359:584-592.
17. Fliser D,Kollerits B,Neyer U, et al.Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study.J Am Soc Nephrol. 2007;18:2600-2608.
18. Kendrick J,Cheung AK,Kaufman JS, et al.FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.J Am Soc Nephrol. 2011;22:1913-1922.
19. Isakova T,Xie H,Yang W, et al.Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.JAMA. 2011;305:2432-2439.
20. Lundberg S,Qureshi AR,Olivecrona S, et al.FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.Clin J Am Soc Nephrol. 2012;7:727-734.
21. Nakano C,Hamano T,Fujii N, et al.Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.Clin J Am Soc Nephrol. 2012;7:810-819.
22. Jean G,Terrat JC,Vanel T, et al.High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.Nephrol Dial Transplant. 2009;24:2792-2796.
23. Wolf M,Molnar MZ,Amaral AP, et al.Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.J Am Soc Nephrol. 2011;22:956-966.
24. Seiler S,Reichart B,Roth D, et al.FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.Nephrol Dial Transplant. 2010;25:3983-3989.
25. Parker BD,Schurgers LJ,Brandenburg VM, et al.The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study.Ann Intern Med. 2010;152:640-648.
26. Smith ER,Ford ML,Tomlinson LA, et al.FGF23 adds value to risk prediction in patients with chronic kidney disease.Bone. 2012;51:830-831.
27. Faul C,Amaral AP,Oskouei B, et al.FGF23 induces left ventricular hypertrophy.J Clin Invest. 2011;121:4393-4408.
28. Medici D,Razzaque MS,Deluca S, et al.FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis.J Cell Biol. 2008;182:459-465.
29. Shalhoub V,Ward SC,Sun B, et al.Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization.Calcif Tissue Int. 2011;89:140-150.
30. Lim K,Lu TS,Molostvov G, et al.Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.Circulation. 2012;125:2243-2255.
31. Zhu D,Mackenzie NC,Millan JL, et al.A protective role for FGF-23 in local defence against disrupted arterial wall integrity?.Mol Cell Endocrinol. 2013;372:1-11.
32. Scialla JJ,Lau WL,Reilly MP, et al.Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.Kidney Int. 2013;83:1159-1168.
33. Lindberg K,Olauson H,Amin R, et al.Arterial Klotho expression and FGF23 effects on vascular calcification and function.PLoS One. 2013;8:e60658-e60658.
34. Roos M,Lutz J,Salmhofer H, et al.Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function.Clin Endocrinol. 2008;68:660-665.
35. Inaba M,Okuno S,Imanishi Y, et al.Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.Osteoporos Int. 2006;17:1506-1513.
36. Tamei N,Ogawa T,Ishida H, et al.Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis.J Atheroscler Thromb. 2011;18:217-223.
37. de Borst MH,Vervloet MG,ter Wee PM, et al.Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.J Am Soc Nephrol. 2011;22:1603-1609.
38. Dai B,David V,Martin A, et al.A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.PLoS One. 2012;7:e44161-e44161.
39. Wohrle S,Henninger C,Bonny O, et al.Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.J Bone Miner Res. 2013;28:899-911.
40. Shalhoub V,Shatzen EM,Ward SC, et al.FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.J Clin Invest. 2012;122:2543-2553.
41. Isakova T,Xie H,Barchi-Chung A, et al.Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.Clin J Am Soc Nephrol. 2011;6:2688-2695.
42. Leaf DE,Wolf M.A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.Am J Kidney Dis. 2013;61:330-336.
43. Endo I,Fukumoto S,Ozono K, et al.Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: Proposal of diagnostic criteria using FGF23 measurement.Bone. 2008;42:1235-1239.
44. Takeuchi Y,Suzuki H,Ogura S, et al.Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.J Clin Endocrinol Metab. 2004;89:3979-3982.
45. Wolf M.Update on fibroblast growth factor 23 in chronic kidney disease.Kidney Int. 2012;82:737-747.
46. Martin A,David V,Quarles LD.Regulation and function of the FGF23/Klotho endocrine pathways.Physiol Rev. 2012;92:131-155.
47. Hu MC,Shiizaki K,Kuro-o M, et al.Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism.Annu Rev Physiol. 2013;75:503-533.
48. Yamashita T, Yoshioka M and Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277: 494-498.
49. Mirams M,Robinson BG,Mason RS, et al.Bone as a source of FGF23: Regulation by phosphate?.Bone. 2004;35:1192-1199.
50. Saini RK,Kaneko I,Jurutka PW, et al.1,25-dihydroxyvitamin d3 regulation of fibroblast growth factor-23 expression in bone cells: Evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.Calcif Tissue Int. 2013;92:339-353.
51. Farrow EG,Yu X,Summers LJ, et al.Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.Proc Natl Acad Sci USA. 2011;108:E1146-E1155.
52. Rodriguez-Ortiz ME,Lopez I,Munoz-Castaneda JR, et al.Calcium deficiency reduces circulating levels of FGF23.J Am Soc Nephrol. 2012;23:1190-1197.
53. Martin A,David V,Li H, et al.Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.Mol Endocrinol. 2012;26:1883-1895.
54. Kurosu H, Ogawa Y, Miyoshi M,et al.Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6130.
55. Ichikawa S,Sorenson AH,Austin AM, et al.Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.Endocrinology. 2009;150:2543-2550.
56. Benet-Pages A,Lorenz-Depiereux B,Zischka H, et al.FGF23 is processed by proprotein convertases but not by PHEX.Bone. 2004;35:455-462.
57. Berndt TJ,Craig TA,McCormick DJ, et al.Biological activity of FGF-23 fragments.Pflugers Arch. 2007;454:615-623.
58. Goetz R,Nakada Y,Hu MC, et al.Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.Proc Natl Acad Sci USA. 2010;107:407-412.
59. Yuan B,Feng JQ,Bowman S, et al.Hexa-D-arginine treatment increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.J Bone Miner Res. 2013;28:56-72.
60. Seidah NG,Prat A.The biology and therapeutic targeting of the proprotein convertases.Nat Rev Drug Discov. 2012;11:367-383.
61. White KE,Carn G,Lorenz-Depiereux B, et al.Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.Kidney Int. 2001;60:2079-2086.
62. Imel EA,Hui SL,Econs MJ.FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.J Bone Miner Res. 2007;22:520-526.
63. Kawai M,Kinoshita S,Kimoto A, et al.FGF23 suppresses chondrocyte proliferation in the presence of soluble alpha-Klotho both in vitro and in vivo.J Biol Chem. 2013;288:2414-2427.
64. Matsumura Y,Aizawa H,Shiraki-Iida T, et al.Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein.Biochem Biophys Res Commun. 1998;242:626-630.
65. Hu MC,Shi M,Zhang J, et al.Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.Faseb J. 2010;24:3438-3450.
66. Smith RC,O'Bryan LM,Farrow EG, et al.Circulating alphaKlotho influences phosphate handling by controlling FGF23 production.J Clin Invest. 2012;122:4710-4715.
67. Larsson T,Nisbeth U,Ljunggren O, et al.Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.Kidney Int. 2003;64:2272-2279.
68. Yamamoto T,Nascimento MM,Hayashi SY, et al.Changes in circulating biomarkers during a single hemodialysis session.Hemodial Int. 2013;17:59-66.
69. Khosravi A,Cutler CM,Kelly MH, et al.Determination of the elimination half-life of fibroblast growth factor-23.J Clin Endocrinol Metab. 2007;92:2374-2377.
70. Goetz R,Nakada Y,Hu MC, et al.Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.Proc Natl Acad Sci USA. 2010;107:407-412.
71. Smith ER,Ford ML,Tomlinson LA, et al.Instability of fibroblast growth factor-23 (FGF-23): Implications for clinical studies.Clin Chim Acta. 2011;412:1008-1011.
72. Yamazaki Y,Okazaki R,Shibata M, et al.Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.J Clin Endocrinol Metab. 2002;87:4957-4960.
73. Shimada T,Muto T,Urakawa I, et al.Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.Endocrinology. 2002;143:3179-3182.
74. Smith ER,McMahon LP,Holt SG.Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs.Clin Chem Lab Med. 2013;51:1971-1981.
75. Shimizu Y,Fukumoto S,Fujita T.Evaluation of a new automated chemiluminescence immunoassay for FGF23.J Bone Miner Metab. 2012;30:217-221.
76. Fischer DC,Mischek A,Wolf S, et al.Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.Ann Clin Biochem. 2012;49:546-553.
77. Smith ER,Cai MM,McMahon LP, et al.Biological variability of plasma intact and C-terminal FGF23 measurements.J Clin Endocrinol Metab. 2012;97:3357-3365.
78. Wolf M.Forging forward with 10 burning questions on FGF23 in kidney disease.J Am Soc Nephrol. 2010;21:1427-1435.
79. Wesseling-Perry K.FGF-23 in bone biology.Pediatr Nephrol. 2010;25:603-608.
80. Juppner H.Phosphate and FGF-23.Kidney Int Suppl. 2011;121:S24-7.
81. Shimada T,Urakawa I,Isakova T, et al.Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.J Clin Endocrinol Metab. 2010;95:578-585.
82. Isakova T.Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.Curr Opin Nephrol Hypertens. 2012;21:334-340.
83. Fassbender WJ,Brandenburg V,Schmitz S, et al.Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.Clin Lab. 2009;55:144-152.
84. Imel EA,Peacock M,Pitukcheewanont P, et al.Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.J Clin Endocrinol Metab. 2006;91:2055-2061.
85. Bacchetta J,Dubourg L,Harambat J, et al.The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease.J Clin Endocrinol Metab. 2010;95:1741-1748.
86. Quarles LD.FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.Am J Physiol Endocrinol Metab. 2003;285:E1-E9.
87. Vervloet MG,van Ittersum FJ,Buttler RM, et al.Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.Clin J Am Soc Nephrol. 2011;6:383-389.
88. Nishida Y,Taketani Y,Yamanaka-Okumura H, et al.Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.Kidney Int. 2006;70:2141-2147.
89. Ito N,Fukumoto S,Takeuchi Y, et al.Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans.J Bone Miner Metab. 2007;25:419-422.
90. Isakova T,Gutierrez O,Shah A, et al.Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.J Am Soc Nephrol. 2008;19:615-623.
91. Petersen PH,Fraser CG,Sandberg S, et al.The index of individuality is often a misinterpreted quantity characteristic.Clin Chem Lab Med. 1999;37:655-661.
92. Ricos C,Iglesias N,Garcia-Lario JV, et al.Within-subject biological variation in disease: Collated data and clinical consequences.Ann Clin Biochem. 2007;44:343-352.
93. Alvarez L,Ricos C,Peris P, et al.Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.Bone. 2000;26:571-576.
94. Cavalier E,Delanaye P,Moranne O.Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: Implications for clinical decision making.Am J Kidney Dis. 2013;61:847-848.
95. Seiler S,Lucisano G,Ege P, et al.Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients.Clin J Am Soc Nephrol. 2013;8:1764-1772.
96. Jia T,Qureshi AR,Brandenburg V, et al.Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.Am J Nephrol. 2013;37:462-471.
97. Fraser CG,Cummings ST,Wilkinson SP, et al.Biological variability of 26 clinical chemistry analytes in elderly people.Clin Chem. 1989;35:783-786.
98. Bhattacharyya N,Wiench M,Dumitrescu C, et al.Mechanism of FGF23 processing in fibrous dysplasia.J Bone Miner Res. 2012;27:1132-1141.
99. Imel EA,Peacock M,Pitukcheewanont P, et al.Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.J Clin Endocrinol Metab. 2006;91:2055-2061.
100. Fliser D,Kollerits B,Neyer U, et al.Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study.J Am Soc Nephrol. 2007;18:2600-2608.
101. Block GA,Wheeler DC,Persky MS, et al.Effects of phosphate binders in moderate CKD.J Am Soc Nephrol. 2012;23:1407-1415.
102. Yilmaz MI,Sonmez A,Saglam M, et al.Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial.Am J Kidney Dis. 2012;59:177-185.
103. Oliveira RB,Cancela AL,Graciolli FG, et al.Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?.Clin J Am Soc Nephrol. 2010;5:286-291.
104. Brandenburg VM,Schlieper G,Heussen N, et al.Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study.Nephrol Dial Transplant. 2010;25:2672-2679.
105. Koiwa F,Kazama JJ,Tokumoto A, et al.Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.Ther Apher Dial. 2005;9:336-339.
106. Covic A,Passlick-Deetjen J,Kroczak M, et al.A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study.Nephrol Dial Transplant. 2013;28:2383-2392.
107. Gonzalez-Parra E,Gonzalez-Casaus ML,Galan A, et al.Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.Nephrol Dial Transplant. 2011;26:2567-2571.
108. Isakova T,Barchi-Chung A,Enfield G, et al.Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.Clin J Am Soc Nephrol. 2013;8:1009-1018.
109. Schouten BJ,Hunt PJ,Livesey JH, et al.FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study.J Clin Endocrinol Metab. 2009;94:2332-2337.
110. Wolf M,Koch TA,Bregman DB.Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.J Bone Miner Res. 2013;28:1793-1803.
111. Schouten BJ,Doogue MP,Soule SG, et al.Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.Ann Clin Biochem. 2009;46:167-169.
112. Khosravi A,Cutler CM,Kelly MH, et al.Determination of the elimination half-life of fibroblast growth factor-23.J Clin Endocrinol Metab. 2007;92:2374-2377.
113. Chong WH,Andreopoulou P,Chen CC, et al.Tumor localization and biochemical response to cure in tumor-induced osteomalacia.J Bone Miner Res. 2013;28:1386-1398.
114. Weber TJ,Liu S,Indridason OS, et al.Serum FGF23 levels in normal and disordered phosphorus homeostasis.J Bone Miner Res. 2003;18:1227-1234.
115. Farrow EG,Imel EA,White KE.Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and alphaKlotho).Best Pract Res Clin Rheumatol. 2011;25:735-747.
116. Ichikawa S,Guigonis V,Imel EA, et al.Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.J Clin Endocrinol Metab. 2007;92:1943-1947.
117. Imel EA,Econs MJ.Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.Pediatr Endocrinol Rev. 2007;4:434-439.
118. Garrett G,Sardiwal S,Lamb EJ, et al.PTH-a particularly tricky hormone: Why measure it at all in kidney patients?.Clin J Am Soc Nephrol. 2013;8:299-312.
119. Gardham C,Stevens PE,Delaney MP, et al.Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.Clin J Am Soc Nephrol. 2010;5:1261-1267.
120. Souberbielle JC,Roth H,Fouque DP.Parathyroid hormone measurement in CKD.Kidney Int. 2010;77:93-100.
121. Divieti P,John MR,Juppner H, et al.Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor.Endocrinology. 2002;143:171-176.
122. Slatopolsky E,Finch J,Clay P, et al.A novel mechanism for skeletal resistance in uremia.Kidney Int. 2000;58:753-761.
123. Isakova T.Comparison of mineral metabolites as risk factors for adverse clinical outcomes in CKD.Semin Nephrol. 2013;33:106-117.
124. Ito N,Fukumoto S,Takeuchi Y, et al.Comparison of two assays for fibroblast growth factor (FGF)-23.J Bone Miner Metab. 2005;23:435-440.
125. Burnett SM,Gunawardene SC,Bringhurst FR, et al.Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.J Bone Miner Res. 2006;21:1187-1196.
126. Wesseling-Perry K,Pereira RC,Wang H, et al.Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.J Clin Endocrinol Metab. 2009;94:511-517.
127. Wesseling-Perry K,Pereira RC,Sahney S, et al.Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.Kidney Int. 2011;79:112-119.
128. Imel EA,Peacock M,Gray AK, et al.Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.J Clin Endocrinol Metab. 2011;96:3541-3549.
129. Burnett SM,Gunawardene SC,Bringhurst FR, et al.Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.J Bone Miner Res. 2006;21:1187-1196.
130. Durham BH,Joseph F,Bailey LM, et al.The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.Ann Clin Biochem. 2007;44:463-466.
131. Bacchetta J,Cochat P,Salusky IB, et al.Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.Pediatr Nephrol. 2012;27:1131-1138.
132. Fernandez-Real JM,Puig J,Serrano M, et al.Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations.PLoS One. 2013;8:e58961-e58961.
133. Ferrari SL,Bonjour JP,Rizzoli R.Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.J Clin Endocrinol Metab. 2005;90:1519-1524.
134. Antoniucci DM,Yamashita T,Portale AA.Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.J Clin Endocrinol Metab. 2006;91:3144-3149.
135. Isakova T,Gutierrez OM,Smith K, et al.Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.Nephrol Dial Transplant. 2011;26:584-591.
136. Moe SM,Zidehsarai MP,Chambers MA, et al.Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.Clin J Am Soc Nephrol. 2011;6:257-264.
137. Di Iorio B,Di Micco L,Torraca S, et al.Acute effects of very-low-protein diet on FGF23 levels: A randomized study.Clin J Am Soc Nephrol. 2012;7:581-587.